{"url_path":"/sec/crvo/8-k/2026-07-14/item-7-01","section_key":"item-7-01","section_title":"Item 7.01 **         **Regulation FD Disclosure**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-07-14","source_url":"https://www.sec.gov/Archives/edgar/data/1053691/0001437749-26-023538-index.html","accession_number":"0001437749-26-023538","cik":"0001053691","ticker":"CRVO","issuer_name":"CervoMed Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1053691/0001437749-26-023538-index.html","primary_entity_key":"0001053691","primary_entity_name":"CervoMed Inc."},"word_count":151,"has_tables":true,"body_markdown":"**Item 7.01**         **Regulation FD Disclosure**\n\n \n\nOn July 14, 2026, CervoMed Inc. (the “Company”) issued a press release announcing clinical, plasma biomarker, and imaging data presented at the Alzheimer's Association International Conference 2026 in London, England related to the Company’s lead drug candidate, neflamapimod, in the treatment of patients with dementia with Lewy bodies. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.\n\n \n\nThe information in this Item 7.01 is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference into any registration statement or other filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing."}